Agree Dr. Friend will only be able to buy/sell for 30 day windows following EOY reporting and the AGM.
They do need to demonstrate that they can manage their collaborations. A 6 month window for reporting data when the readouts are so close does not demonstrate that they know what is going on with their drug. If a trial readout milestone is 1-2 years away then a 6 month window is acceptable. If the dipg interim cohort has been locked then the stat analysis, review, report to Kazia will all be known to virtually the hour. As always hopeful that this management teams only decision in the next few months is to recommend accepting an offer.
- Forums
- ASX - By Stock
- KZA
- Ann: Paxalisib receives Fast Track Designation from US FDA
Ann: Paxalisib receives Fast Track Designation from US FDA, page-20
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)